Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Matcham

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Journal of Neuroscience Methods|June 2, 2007
GDNF in Parkinson's disease: the perils of post-hoc powerJames Matcham, Michael P McDermott, Anthony E Lang
International Journal of Technology Assessment in Health Care|February 4, 2014
Update on romiplostim and eltrombopag indirect comparisonKaty Cooper, James Matcham, Kawitha Helme, et al.
Pharmaceutical Statistics|March 19, 2016
Decision-making in early clinical drug developmentPaul Frewer, Pat Mitchell, Claire Watkins, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 14, 2003
Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysisIain C Macdougall, James Matcham, Stephen J Gray, et al.
Statistics in Biopharmaceutical Research|April 1, 2014
A Quantitative Process for Enhancing End of Phase 2 DecisionsTony Sabin, James Matcham, Sarah Bray, et al.
Pharmaceutical Statistics|February 27, 2010
Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trialsJames Matcham, Steven Julious, Stephen Pyke, et al.
Pharmaceutical Statistics|January 29, 2011
Making available information from studies sponsored by the pharmaceutical industry: some current practicesMichael O'Kelly, Steven A Julious, Stephen Pyke, et al.
Pharmaceutical Statistics|January 29, 2011
The potential for bias in reporting of industry-sponsored clinical trialsStephen Pyke, Steven A Julious, Simon Day, et al.
Pharmaceutical Statistics|January 12, 2018
Integrating dose estimation into a decision-making framework for model-based drug developmentJames Dunyak, Patrick Mitchell, Bengt Hamrén, et al.
Pharmaceutical Statistics|December 14, 2011
A statistician's perspective on biomarkers in drug developmentMartin Jenkins, Aiden Flynn, Trevor Smart, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Neuroscience Methods|June 2, 2007
GDNF in Parkinson's disease: the perils of post-hoc powerJames Matcham, Michael P McDermott, Anthony E Lang
International Journal of Technology Assessment in Health Care|February 4, 2014
Update on romiplostim and eltrombopag indirect comparisonKaty Cooper, James Matcham, Kawitha Helme, et al.
Pharmaceutical Statistics|March 19, 2016
Decision-making in early clinical drug developmentPaul Frewer, Pat Mitchell, Claire Watkins, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 14, 2003
Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysisIain C Macdougall, James Matcham, Stephen J Gray, et al.
Statistics in Biopharmaceutical Research|April 1, 2014
A Quantitative Process for Enhancing End of Phase 2 DecisionsTony Sabin, James Matcham, Sarah Bray, et al.
Pharmaceutical Statistics|February 27, 2010
Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trialsJames Matcham, Steven Julious, Stephen Pyke, et al.
Pharmaceutical Statistics|January 29, 2011
Making available information from studies sponsored by the pharmaceutical industry: some current practicesMichael O'Kelly, Steven A Julious, Stephen Pyke, et al.
Pharmaceutical Statistics|January 29, 2011
The potential for bias in reporting of industry-sponsored clinical trialsStephen Pyke, Steven A Julious, Simon Day, et al.
Pharmaceutical Statistics|January 12, 2018
Integrating dose estimation into a decision-making framework for model-based drug developmentJames Dunyak, Patrick Mitchell, Bengt Hamrén, et al.
Pharmaceutical Statistics|December 14, 2011
A statistician's perspective on biomarkers in drug developmentMartin Jenkins, Aiden Flynn, Trevor Smart, et al.
Pageof 2